IL207421A0 - Therapeutic peptidomimetic macrocycles - Google Patents

Therapeutic peptidomimetic macrocycles

Info

Publication number
IL207421A0
IL207421A0 IL207421A IL20742110A IL207421A0 IL 207421 A0 IL207421 A0 IL 207421A0 IL 207421 A IL207421 A IL 207421A IL 20742110 A IL20742110 A IL 20742110A IL 207421 A0 IL207421 A0 IL 207421A0
Authority
IL
Israel
Prior art keywords
peptidomimetic macrocycles
therapeutic
therapeutic peptidomimetic
macrocycles
peptidomimetic
Prior art date
Application number
IL207421A
Other languages
English (en)
Original Assignee
Aileron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc
Publication of IL207421A0 publication Critical patent/IL207421A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL207421A 2008-02-08 2010-08-04 Therapeutic peptidomimetic macrocycles IL207421A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732608P 2008-02-08 2008-02-08
US12038008P 2008-12-05 2008-12-05
PCT/US2009/000837 WO2009099677A2 (en) 2008-02-08 2009-02-09 Therapeutic peptidomimetic macrocycles

Publications (1)

Publication Number Publication Date
IL207421A0 true IL207421A0 (en) 2010-12-30

Family

ID=40952614

Family Applications (2)

Application Number Title Priority Date Filing Date
IL207421A IL207421A0 (en) 2008-02-08 2010-08-04 Therapeutic peptidomimetic macrocycles
IL243240A IL243240A (en) 2008-02-08 2015-12-20 Therapeutic peptidomimetic macrocycles

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL243240A IL243240A (en) 2008-02-08 2015-12-20 Therapeutic peptidomimetic macrocycles

Country Status (12)

Country Link
US (4) US20090275519A1 (OSRAM)
EP (2) EP2926827A3 (OSRAM)
JP (2) JP2011511076A (OSRAM)
KR (1) KR20100126361A (OSRAM)
CN (2) CN101980718A (OSRAM)
BR (1) BRPI0907754A2 (OSRAM)
CA (1) CA2714251C (OSRAM)
DE (1) DE112009000300T5 (OSRAM)
GB (1) GB2471588A (OSRAM)
IL (2) IL207421A0 (OSRAM)
WO (1) WO2009099677A2 (OSRAM)
ZA (1) ZA201005741B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008076904A1 (en) 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US7981999B2 (en) 2007-02-23 2011-07-19 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN101980718A (zh) 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
AU2009294875C1 (en) * 2008-09-22 2015-05-14 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
AU2010298338A1 (en) * 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
KR20130115108A (ko) 2010-05-28 2013-10-21 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 올리고－벤즈아미드 화합물 및 이의 용도
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012051405A1 (en) 2010-10-13 2012-04-19 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
EP2651964B1 (en) 2010-12-15 2018-02-28 The Research Foundation of State University of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
JP6642887B2 (ja) * 2014-04-02 2020-02-12 ユニバーシティー オブ ロチェスター アルファヘリックスを模倣した大環状ペプチドミメティック
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
CN106999541A (zh) * 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
AU2016232833A1 (en) * 2015-03-18 2017-10-12 Dana-Farber Cancer Institute, Inc. Selective Mcl-1 binding peptides
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) * 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
WO2017053391A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
RS60662B1 (sr) 2015-10-27 2020-09-30 Hoffmann La Roche Peptidni makrocikli protiv acinetobacter baumannii
WO2017075349A2 (en) * 2015-10-30 2017-05-04 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
WO2018017922A2 (en) 2016-07-22 2018-01-25 Massachusetts Institute Of Technology Selective bfl-1 peptides
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
WO2018232062A1 (en) 2017-06-15 2018-12-20 University Of Washington Macrocyclic polypeptides
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11286299B2 (en) 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
JP2022525416A (ja) * 2019-03-15 2022-05-13 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子およびその使用
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
WO2023069332A1 (en) * 2021-10-22 2023-04-27 Merck Sharp & Dohme Llc Cell permeable macrocyclic peptides useful for eif4e cap-binding site inhibition

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753819A (en) * 1903-04-08 1904-03-01 George Jones Atkins Electrode.
US5712418A (en) * 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
EP0488258B1 (en) 1990-11-27 1996-04-17 Fuji Photo Film Co., Ltd. Propenamide derivatives, polymers, copolymers and use thereof
US5364851A (en) * 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
EP1251135A3 (en) * 1992-04-03 2004-01-02 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) * 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US5663316A (en) * 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) * 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
JP2001524301A (ja) * 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
CA2325572A1 (en) 1998-04-15 1999-10-21 Aventis Pharmaceuticals Products Inc. Process for the preparation of resin-bound cyclic peptides
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
CA2368431C (en) * 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
EP1210098A1 (en) * 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
AU2001284942A1 (en) * 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
WO2002064790A2 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
CA2471719A1 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004022580A2 (en) * 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1581904A2 (en) * 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
JP2007537989A (ja) 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PL1768966T3 (pl) * 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
US7745573B2 (en) * 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
WO2008076904A1 (en) * 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981999B2 (en) * 2007-02-23 2011-07-19 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101623985B1 (ko) * 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
EP2152294B1 (en) * 2007-05-02 2017-07-26 Dana-Farber Cancer Institute, Inc. A bad bh3 domain peptide for use in treating or delaying the onset of diabetes.
WO2009042237A2 (en) * 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
US20100295201A1 (en) * 2007-11-20 2010-11-25 Asahi Kasei Construction Materials Corporation Process for producing heat curing resin foamed plate
CN101980718A (zh) 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
CA2737922A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
JP2011511076A (ja) 2011-04-07
DE112009000300T5 (de) 2011-01-20
EP2242503A4 (en) 2012-04-25
EP2926827A3 (en) 2015-11-04
CN101980718A (zh) 2011-02-23
US8808694B2 (en) 2014-08-19
GB201014734D0 (en) 2010-10-20
CA2714251C (en) 2017-08-15
WO2009099677A3 (en) 2009-12-17
CA2714251A1 (en) 2009-08-13
GB2471588A (en) 2011-01-05
US20090275519A1 (en) 2009-11-05
US20120149648A1 (en) 2012-06-14
ZA201005741B (en) 2018-11-28
US20190071469A1 (en) 2019-03-07
BRPI0907754A2 (pt) 2015-07-21
JP2015078208A (ja) 2015-04-23
US20150038430A1 (en) 2015-02-05
AU2009210682A1 (en) 2009-08-13
CN104474529A (zh) 2015-04-01
WO2009099677A2 (en) 2009-08-13
EP2242503A2 (en) 2010-10-27
KR20100126361A (ko) 2010-12-01
EP2926827A2 (en) 2015-10-07
IL243240A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL243240A (en) Therapeutic peptidomimetic macrocycles
IL211836A0 (en) Peptidomimetic macrocycles
IL219178A0 (en) Improved peptidomimetic macrocycles
IL212748A0 (en) Peptidomimetic macrocycles with improved properties
PL2603600T3 (pl) Makrocykle peptidomometyczne
GB0811304D0 (en) Therapeutic agents
IL206654A0 (en) Combination therapy
GB0908957D0 (en) Therapeutic agents
BRPI0918833A2 (pt) macrociclos peptidomiméticos
GB0819593D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0803054D0 (en) Medicament
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0803948D0 (en) Combination therapy
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0811715D0 (en) Therapeutic agents
HK1145988A (en) Therapeutic peptidomimetic macrocycles
GB0814895D0 (en) An improved hydrotherapy unit
HK1160144A (en) Peptidomimetic macrocycles
HK1160145A (en) Peptidomimetic macrocycles
HK1161104A (en) Peptidomimetic macrocycles

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed